cmp semaglutide/cyan 2.5mg/0.5mg/ml inj Positive results in trial testing #GLP-1 targeting #diabetes/#weight-loss medicine semaglutide (Ozempic, Wegovy) in treatment-seeking patents with #alcohol use disorder (AUD) who were also obese. Alcohol consumed dropped over 70% after 26 weeks Semaglutide/B12 5/0.5mg/ml (2.5 ml) 12.5

Initially, shots might be given more frequently to establish adequate levels, but over time, maintenance doses can be spaced out to once every few months

Post-marketing surveillance and FDA Adverse Event Reporting System (FAERS) data have documented isolated reports of patients experiencing dyspnea while taking GLP-1 medications, but establishing causality remains challenging

Another common GI side effect is vomiting

In vitro validation studies revealed that febuxostat, but not colchicine, reduced lipolysis in cultured adipocytes

doi:10.1089/ars.2005.7.32 Rdig par Benjamin Dariouch Benjamin Dariouch est Responsable valorisation scientifique & Expert nutraceutique chez Nutri&Co